DW Healthcare Partners Successfully Sells LKC Technologies to AMETEK, Enhancing Eye Care Solutions
On February 3, 2026, DW Healthcare Partners (DWHP), a private equity firm dedicated to the healthcare sector, announced the successful sale of LKC Technologies to AMETEK, Inc., a renowned publicly traded company. LKC Technologies, known for its pivotal role in visual electrophysiology, has been instrumental in advancing eye care through innovative diagnostic solutions over the past 35 years. The company specializes in creating accessible technologies that improve functional retinal assessments, which are crucial for preserving vision.
LKC's most notable product, the handheld electroretinography (ERG) device termed RETeval, plays a significant role in diagnosing and managing diseases affecting the retina and optic nerve. This device delivers reliable, objective data to eye care professionals, thus enhancing their ability to diagnose sight-threatening conditions at earlier stages.
The partnership between LKC Technologies and DW Healthcare Partners, particularly through the Founders Fund, has fostered a culture of innovation and growth. Dina Dubey, CEO of LKC Technologies, expressed her gratitude towards DWHP, noting their exceptional support during the past three years. She emphasized how DWHP played a crucial role in the company’s significant growth trajectory, helping LKC to reach new operational heights.
"We appreciate DWHP's partnership which has helped us not only to scale our operations but also to increase awareness about the importance of functional retinal testing in preventing vision loss," Dubey said.
Gabe Becher, Managing Director at DWHP, shared his enthusiasm about the sale, describing LKC Technologies as a company that aligns perfectly with DWHP's mission of investing in organizations that make a profound impact on patient health outcomes. The collaboration allowed them to leverage their expertise and capital to push LKC’s agenda forward, ultimately benefitting patients reliant on reliable eye care solutions.
The successful sale highlights DWHP's strategy of strategically investing in mid-stage healthcare firms and providing them with the necessary capital and guidance to innovate within their fields. As of December 31, 2025, DWHP managed over $2.7 billion in assets across its six funds, led by a team of seasoned executives boasting over 155 years of combined experience in the healthcare industry.
William Blair served as the exclusive financial adviser to LKC Technologies during this transition, further solidifying the professional credibility of the sale. The acquisition by AMETEK promises to broaden the reach of LKC's innovative technologies, thereby continuing its mission of improving patient outcomes in eye health.
This sale marks a significant milestone not just for LKC Technologies but also for DW Healthcare Partners, as they continue to nurture and grow ventures that play a vital role in enhancing healthcare services worldwide. As LKC moves forward under AMETEK’s umbrella, the company is set to expand its influence and continue providing cutting-edge solutions to eye care professionals, reinforcing its commitment to advancing the field of visual electrophysiology and patient care more broadly.
LKC's most notable product, the handheld electroretinography (ERG) device termed RETeval, plays a significant role in diagnosing and managing diseases affecting the retina and optic nerve. This device delivers reliable, objective data to eye care professionals, thus enhancing their ability to diagnose sight-threatening conditions at earlier stages.
The partnership between LKC Technologies and DW Healthcare Partners, particularly through the Founders Fund, has fostered a culture of innovation and growth. Dina Dubey, CEO of LKC Technologies, expressed her gratitude towards DWHP, noting their exceptional support during the past three years. She emphasized how DWHP played a crucial role in the company’s significant growth trajectory, helping LKC to reach new operational heights.
"We appreciate DWHP's partnership which has helped us not only to scale our operations but also to increase awareness about the importance of functional retinal testing in preventing vision loss," Dubey said.
Gabe Becher, Managing Director at DWHP, shared his enthusiasm about the sale, describing LKC Technologies as a company that aligns perfectly with DWHP's mission of investing in organizations that make a profound impact on patient health outcomes. The collaboration allowed them to leverage their expertise and capital to push LKC’s agenda forward, ultimately benefitting patients reliant on reliable eye care solutions.
The successful sale highlights DWHP's strategy of strategically investing in mid-stage healthcare firms and providing them with the necessary capital and guidance to innovate within their fields. As of December 31, 2025, DWHP managed over $2.7 billion in assets across its six funds, led by a team of seasoned executives boasting over 155 years of combined experience in the healthcare industry.
William Blair served as the exclusive financial adviser to LKC Technologies during this transition, further solidifying the professional credibility of the sale. The acquisition by AMETEK promises to broaden the reach of LKC's innovative technologies, thereby continuing its mission of improving patient outcomes in eye health.
This sale marks a significant milestone not just for LKC Technologies but also for DW Healthcare Partners, as they continue to nurture and grow ventures that play a vital role in enhancing healthcare services worldwide. As LKC moves forward under AMETEK’s umbrella, the company is set to expand its influence and continue providing cutting-edge solutions to eye care professionals, reinforcing its commitment to advancing the field of visual electrophysiology and patient care more broadly.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.